Update on Candida Infection Nov. 2010
|
|
- Ophelia Webster
- 6 years ago
- Views:
Transcription
1 Update on Candida Infection Nov Gary Wong Pharmacy Clinical site leader University Health Network Course coordinator University of Toronto
2 Goals What is an yeast infection Risk factors for yeast infections Understand the mechanism of action, kinetics, and adverse affects of antifungal agents Understand the roles of various antifungal agents as define by the guidelines
3 Fungi Yeast like Candida albicans C. glabrata C. parapsilosis C. tropicalis C. krusei Pneumocyctis jirovecii Crytococcus neoformans Blastomyces dermatitidis Histoplama capsulatum Molds Aspergillus spp. mucormycosis
4 Oropharyngeal Candidiasis Esophageal Candidiasis Candidiasis (line, Gut) Candida Vaginitis
5 Nosocomial Bloodstream Infections in US Hospitals: Rank Pathogen BSI per 10,000 admissions Total (n=20,978) % BSI % Crude Mortality ICU (n=10,515 ) Non-ICU (n=10,515) Total ICU 1. CoNS S. aureus Enterococcus spp. Non- ICU Candida spp E. coli Klebsiella spp BSI=blood stream infection; CoNS=coagulase-negative staphylococci Surveillance and Control of Pathogens of Epidemiologic Importance (SCOPE) study Wisplinghoff H, et al. Clin Infect Dis. 2004;39:
6 Risk Factors for Candida Multiple antibiotics- > 3 antibiotics High APACHE score - predictive of infection and mortality Burns- burn size > 50% Central venous lines- CV catheters, Hickman Renal failure- prior hemodialysis TPN, total parenteral nutrition Multiple Sites (>2) colonization Major surgery- abdominal, cardiothoracic Transplantation- Liver Neutropenia- depth and duration of neutropenia Duration of stay in ICU Pfaller, Epidemmiology Clin Micr Rev :
7 Risk Factors Invasive Candidiasis High-risk patients Surgery Leukopenia Burns Premature infants Risk Factors ICU >7 days CVCs Antibiotics TPN Colonization If candidemia develops ~40% die ~60% survive Rex JH, et al. Adv Intern Med. 1998;43: Pappas PG, et al. Clin Infect Dis. 2003;37:
8 Antifungal therapy Cell membrane Polyene: Amphotericin B, Nystatin Azoles: Fluconazole, itraconazole, voriconazole, Posaconazole. Cell wall Echinocandins: Caspofungin, Micafungin, Anidulafungin Nucleoside analog: Flucytosine
9 Amphotericin B Nystatin
10 Amphotericin B A Polyene molecule which is not water soluble Comes from Streptomyces nodosus Binds to the ergosterol molecules in the membrane of the fungus. This binding makes the membrane dysfunctional and electrolyte imbalances occur. A broad spectrum activity Kills most Candida spp. and Aspergillosis.
11 Amphotericin B
12 Adverse effects Amphotericin B Infusion related side effects: fever, chills, rigors, aches, and hypoxia. Nephrotoxicity in 25% of patients Hypokalemia Hypomagnesemia Drug interactions Avoid other nephrotoxic agents
13 Lipid Amphotericin B products Abelcet lipid complex, AmBisome liposomal These products are Amphotericin which is combined with a lipid molecule which binds the amphotericin B. Prodrug.
14 phospholipid bilayer amphotericin B molecules Ref: Clin Infect Dis 1996; 22(Suppl2):S
15 amphotericin B - OH + OH OH + OH - Hydrophilic Region OH OH OH OH Hydrophobic Region OH OH OH OH - OH Schematic Representation + OH OH + OH cholesterol - Hydrophilic Region
16 Lipid Amphotericin B products AmBisome Less infusion related side effects Less renal toxicity Same efficacy Dose: 3mg/kg vs 5mg/kg Febrile Neutropenia: Wingard CID 2000:31: Invasive Aspergillosis: Cornely CID 2007; 44:
17 Organism Comparative In Vitro Activity Against Candida MIC 90 (µg/ml) n POS FLZ ITZ VOR AMB All Candida spp * C albicans * C glabrata * C parapsilosis C tropicalis C krusei C lusitaniae C guilliermondii C dubliniensis Candida spp *Number of strains tested against AMB was slightly less for all Candida (n = 6921), C albicans (n = 3517), and C glabrata (n = 1192). Includes strains of C famata, C kefyr, C lipolytica, C pelliculosa, C pseudotropicalis, C rugosa, C sphaerica, C stellatoidea, and C zeylanoides. Sabatelli F et al. Antimicrob Agents Chemother. 2006:
18 Organism Comparative In Vitro Activity Against Molds and Other Fungi n MIC 90 (µg/ml) POS ITZ VOR AMB All molds Aspergillus spp Dimorphic fungi ND 0.5 Fusarium spp Zygomycetes Agents of chromoblastomycosis, mycetoma, and phaeohyphomycosis ND 32.0 Other molds* *Includes strains of Acremonium, Basidiomycetes, Bjerkandera, Coprinus, Paecilomyces, Pseudallescheria, Schizophyllum, and Trichophyton. Sabatelli F et al. Antimicrob Agents Chemother. 2006:
19 Azoles Inhibit CYP450 enzyme lanosterol 14- demethylase prevent conversion of lanosterol to ergosterol significant drug interactions
20 Azoles
21 Triazoles Adverse effects Well-tolerated Rare instances of elevated liver enzymes Visual (Vori) QT (Vori and Posa) Resistance C. krusei, C. glabrata with fluconazole
22 Pharmacokinetics Fluconazole Voriconazole Posaconazole Dose 400 mg 200 mg 400 mg (800 mg empiric) absorption 90% 90% N/a Protien binding 11% 99.5% 80% C max (mg/l) ½ Life (hr) Elimination Renal 80% Hepatic Hepatic CID 2009: 48: Tx Med Letter Jan 2008; 6 (65)
23 Pharmacokinetics Pearls Fluconazole Voriconazole Posaconazole Food None Decrease Increase Hepatic Weak CYP2C9 CYP CYP3A4 CYP2C19 CYP3A4 (400% fatty) CYP3A4 PPI None Omeprazole Increase 15-41% Place in Therapy Candida limited spectrum Aspergillosis SE Esomeprazole Derease 33% Prophylaxis BMT Limited indications CID 2009: 48: Tx Med Letter Jan 2008; 6 (65) Vori vs AMB. NEJM 2002; 347: , 2002 Cornely OA, N Engl J Med 2007; 356:
24 Echinocandins New class of agents -Caspofungin (Cancidas, Merck, 2001) -Micafungin (FK463, Fujisawa, 2007) -Anidulafungin (Pfizer, 2008)
25 Echinocandins
26 Echinocandin Echinocandin antifungal, amine polypeptide. Inhibits synthesis of ß-(1,3)-D-glucan Disrupts cell wall integrity & osmotic stability Causes cell lysis ß-(1,3)-D-glucan not present in mammalian cells
27 Echinocandins Mannoproteins -(1,6)-Glucan -(1,3)-Glucan GS Ergosterol Chitin -(1,3)- Glucan Synthesis
28 Echinocandins Pharmacokinetic Poor absorbed orally, only used IV Well distributed therapeutic concentrations in lung, liver, large intestine, spleen, kidney Minimal CSF & eye penetration. Elimination: Hepatic
29 Pharmacokinetics Caspofungin Micafungin Anidulafungin Dose 50 mg 50 mg 50 mg (target dose) (70/50) (100) 200/100 Protien binding 96.5% 99.5% 80% C max (mg/l) ½ Life (hr) Elimination Hepatic Hepatic Chem&Hepatic Hydrolysis, N-acetylation and spontaneous degratation Stone ACC 2002;46: , Mukai ICAAC 2001 Thye ICAAC 2002, Abstracts A-34, 1391, 1392 Dowell et al. J Clin Pharmacol 2004;44: Hiemenz et al. AAC 2005;49: Primarily hepatic by arylsulfatase and COMT Slow non-enzymatic degradation to inactive metabolites
30 Echinocandin S/E Neutropenia (Micafungin 1.2%, Anidulafungin 1%) thrombocytopenia (Caspofungin <4%) Nausea and vomiting 3% Elevated AST/ALT: (Caspofungin 11-24%). Hypokalemia: (Caspofungin <4%). Phlebitis: (Caspofungin, Anidulafungin) Eschenauer G et al. Ther Clin Risk Man 2007;3:71-97 Pappas P, Rotstein C, Betts RF et al. CID 2007;45:
31 In Vitro Activity of Echinocandins Against Bloodstream Isolates of Candida Species Species No. of isolates tested Results for: ANID CASP MICA MIC 90 % 2 g/ml MIC 90 % 2 g/ml MIC 90 % 2 g/ml C. albicans 2, C. glabrata C. tropicalis C. krusei C. parapsilosis C. guilliermondii All Candida spp. 5, Pfaller MA et al. J Clin Microbiol 2008;46:
32 In Vitro Activity Antifungal Agents Against Aspergillus fumigatus Antifungal drug MIC 50 µg/ml MIC 90 µg/ml Anidulafungin Amphotericin B Caspofungin a Itraconazole Voriconazole < a Expressed as minimal effective concentration (MEC) Vazquez JA, Sobel JD. Clin Infect Dis 2006;43:
33 Case 1 HS 45 yrs male present with oral thrush and Rx Nystatin 5mL S and S, then fluconazole. Present to General surgery floor with Intra abd infection, Day 3 goes to OR to have a collection drained, and now day 4 ICU being consulted. Patient temp 39.0 C and WBC is 12.0 PHM: Liver Tx August 2010 for Hepatitis B Recent thrush 3 weeks ago Hepatitis B in 1990 from blood transfusion SBP 2009 (E.coli) Tx Cipro Gi bleed 2008, Ascities, Jaundice, Allergies: None Current medication Tacrolimus 4mg bid, Prednisone 20 mg daily Lamivudine 100 mg daily Ceftriaxone 1g iv daily Metronidazole 500mg iv q12h. Morphine 2-4mg q4h PRN
34 Risk Factors for Candida Multiple antibiotics- > 3 antibiotics High APACHE score - predictive of infection and mortality Burns- burn size > 50% Central venous lines- CV catheters, Hickman Renal failure- prior hemodialysis TPN, total parenteral nutrition Multiple Sites (>2) colonization Major surgery- abdominal, cardiothoracic Transplantation- Liver Neutropenia- depth and duration of neutropenia Duration of stay in ICU Pfaller, Clin Micr Rev :
35 Risk level Temperature Prophylaxis Treatment Theories Empiric/Pre emptive Specific Colonization Ag test: 1,3 glucan Blood and sterile site positive Immunosuppressive Rx Antibiotics Central lines TPN Surgery Days in ICU Remote Probable disease Proven
36 Antifungal Prophylaxis High risk SICU Meta-analysis 45 RCT trials review used only 6 RCT trials Development of Candidemia and nonbloodstream IFI Konstantinos CCM :
37 Antifungal Prophylaxis High risk SICU Meta-analysis Mortality Konstantinos CCM :
38 Empiric Therapy Double blinded, RCT, 26 us hospital yrs older, > than 96 hours ICU, and fever (38.3c) three occassions APACHE II >16 Broad spectrum antibiotic Central venous catheter Exclusion LFTS 5 times the upper limit neutropenia, HIV, organ or bone marrow transplantation, burns Schuster, Ann Intern Med. 2008; 149:83-90.
39 Therapy Empiric Therapy Fluconazole 800 mg for 14 days Placebo for 14 days Outcome at 4 days 38.3C, fungal infection, use of antifungal, D/C therapy from S/E Secondary: Discharge, mortality at 30 days Assessment by committee of 6 members Schuster, Ann Intern Med. 2008; 149:83-90.
40 Results Fluconazole (133) Placebo(137) Success: 44 (36%) 48 (38%) (RR, 0.95 [CI, 0.69 to 1.32]; P 0.78) Mortality: 29 (24%) 22 (17%) (RR, 1.36 [CI, 0.82to 2.24]; P 0.23) Schuster, Ann Intern Med. 2008; 149:83-90.
41 Candida score Non neutropenic Critically Ill Patients. Prospective observational Multi-center (70 hosp) study in Spain 1699 patients >18 yrs, 7 to 73 days ICU, May 1988 to Jan 1999 Neutropenic patients excluded Surveillance: Stats Weekly: ET, GI aspirate, Urine On discretion: Blood, Lines, feces, wound, drainage patients with sepsis had Ophthalmic exams 65% of the data was used to calculate odds ratio, logistic regression and Form the score 35% of the data was used to validate the model Power of the score was evaluated receiver operating characteristic Leon CCM :
42 Candida score Non neutropenic Critically ill Patients. Number (%) APACHE II Mortality Odds Ratio 95% Non-Colonized 719 (43%) % 1 Colonized Unifocal Multi-focal 103 (26.5%) 252 (50.9%) % 50.9% 1.04 ( ) 1.54 ( ) Proven Candida infection 97 (5.8%) % 3.2( ) Candidemia 58, Endophthalmitis 6 Peritonitis 30, Peritonitis and blood 3 Leon CCM :
43 Candida score Non neutropenic Critical ill Patients. Leon CCM :
44 Candida score Variable Coefficient Values TPN Surgery Multi-focal colonization Severe Sepsis Total =Score Value of 2.5= sensitivity of 81%, specific 74% Risk ratio= % CI proven fungal infection Leon CCM :
45 Case 1 HS 45 yrs male present with oral thrush and Rx Nystatin 5mL S and S, then fluconazole. Present to General surgery floor with Intra abd infection, Day 3 goes to OR to have a collection drained, and now day 4 ICU being consulted. Patient temp 39.0 C and WBC is 12.0 PHM: Liver Tx August 2010 for Hepatitis B Recent thrush 3 weeks ago Hepatitis B in 1990 from blood transfusion SBP 2009 (E.coli) Tx Cipro Gi bleed 2008, Ascities, Jaundice, Allergies: None Current medication Tacrolimus 4mg bid, Prednisone 20 mg daily Lamivudine 100 mg daily Ceftriaxone 1g iv daily Metronidazole 500mg iv q12h. Morphine 2-4mg q4h PRN
46 Antifungal vs Time 192 patients in 4 US Hosp ( ) Mortality % Day <1 Clin Inf Dis 2006; 43:25-31 Day 1 Day 2 Time to therapy Day >3 All Pts Appropriate P<0.0009
47 Clinical Infectious Diseases 2009; 48:503 35
48 Therapeutic concepts Prophylaxis ICU For ICU patients, fluconazole at a dosage of 400 mg (6 mg/kg) daily is recommended for high-risk patients in adult units with a high incidence of invasive candidiasis (B-I). Clinical Infectious Diseases 2009; 48:503 35
49 Invasive Candidiasis RCT Fluconazole vs others 3 RCT of Amphotericin vs Fluconazole Rex, J N Engl J Med 1994;331: Phillips, P Eur J Clin Micr ID 1997:16: Anaissie E; CID 1996;23: Anidulafungin vs Fluconazole Anidul 200/100mg vs Fluconazole 800/400mg Annette C; NEJM 2007; 356:
50 Invasive Candidiasis RCT Echinocandins vs others Caspofungin vs AmB Caspo 70/50 vs AmB 0.6 mg/kg Mora-Duarte J N Engl J Med : Micafungin vs other Mica vs Lipid AmB 3mg/kg Kuse, ER, et al. Lancet 2007;362(9330): Mica 100mg, Mica 150mg vs Caspo 70/50mg Pappas PG, Clin Infect Dis 2007; 45:
51 Invasive Candidiasis RCT Voriconazole vs others Voriconazole vs Lipid Amb Vori 6mg/kg then 3mg/kg vs Lipid AmB 0.3 mg/kg Bj Kullberg, Lancet :
52 HS: Blood gram stain grows Yeast What agent would you choose? Fluconazole or Enchinocandin (A-I) When would you prefer Enchinocandin? Echinocandin for (A-III) Unstable patients Patient With previous azole exposure Clinical Infectious Diseases 2009; 48:503 35
53 Cultures non abicans Germ tube test Negative non albicans
54 Clinical Infectious Diseases 2009; 48:503 35
55 HS: Blood gram stain grows C. krusei What agent would you choose? Step down therapy Enchinocandin IV therapy Voriconazole oral therapy Clinical Infectious Diseases 2009; 48:503 35
56 Organism Comparative In Vitro Activity Against Candida MIC 90 (µg/ml) n POS FLZ ITZ VOR AMB All Candida spp * C albicans * C glabrata * C parapsilosis C tropicalis C krusei C lusitaniae C guilliermondii C dubliniensis Candida spp *Number of strains tested against AMB was slightly less for all Candida (n = 6921), C albicans (n = 3517), and C glabrata (n = 1192). Includes strains of C famata, C kefyr, C lipolytica, C pelliculosa, C pseudotropicalis, C rugosa, C sphaerica, C stellatoidea, and C zeylanoides. Sabatelli F et al. Antimicrob Agents Chemother. 2006:
57 Vori Mic J CLINICAL MICRO Mar. 2006, 44:
58 HS: Blood gram stain grows C. glabrata What agent would you choose? Step down therapy Enhinocandin continue Azole clinically improving, and follow-up culture negative (B- III) MIC (14 days) Clinical Infectious Diseases 2009; 48:503 35
59 Organism Comparative In Vitro Activity Against Candida MIC 90 (µg/ml) n POS FLZ ITZ VOR AMB All Candida spp * C albicans * C glabrata * C parapsilosis C tropicalis C krusei C lusitaniae C guilliermondii C dubliniensis Candida spp *Number of strains tested against AMB was slightly less for all Candida (n = 6921), C albicans (n = 3517), and C glabrata (n = 1192). Includes strains of C famata, C kefyr, C lipolytica, C pelliculosa, C pseudotropicalis, C rugosa, C sphaerica, C stellatoidea, and C zeylanoides. Sabatelli F et al. Antimicrob Agents Chemother. 2006:
60 Fluc and Vori vs C. glabrata Pfaller, Clin Micr Rev :
61 HS: Blood gram stain grows C. parapsilosis What agent would you choose? Step down therapy Candida parapsilosis Fluconazole Enchinocandin if Clinically improving and follow-up culture negative (B-III) Clinical Infectious Diseases 2009; 48:503 35
62 Canadian Approvals? flucytosine 1994 fluconazole 1996 itraconazole 1995 ketoconazole 1997 ABLC (Abelcet) 2000 liposomal amphotericin B (AmBisome) 2001 amphotericin B 2001 caspofungin 2004 voriconazole 2007 micafungin 2007 posaconazole 2008 Anidulafungin
63 Questions
Current options of antifungal therapy in invasive candidiasis
Current options of antifungal therapy in invasive candidiasis Saloua Ladeb Bone Marrow Transplant Center Tunis HAMMAMET 24 th April 2012 DEFINITION One or more positive results on blood culture for Candida
More informationAntifungal Update. Candida: In Vitro Antifungal Susceptibility Testing
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS
ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS COMMERCIAL RELATIONS DISCLOSURE 2500 9000 15000 Astellas Gilead Sciences Pfizer Inc Expert advice Speaker s bureau Speaker s bureau OUTLINE OF THE PRESENTATION
More informationAntifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco 3/3 blood cultures are positive for an unidentified
More informationAntifungal Update 2/24/11. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationFungal Infection in the ICU: Current Controversies
Fungal Infection in the ICU: Current Controversies Andrew F. Shorr, MD, MPH, FCCP, FACP Washington Hospital Center Georgetown University, Washington, DC Disclosures I have served as a consultant to, researcher/investigator
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationObjec&ves. Clinical Presenta&on
Michelle A. Barron, MD Associate Professor of Medicine Division of Infectious Diseases University of Colorado Denver Objec&ves Determine who is at risk for invasive candidiasis. Understand whether prophylaxis
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationCURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR
CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS Dr AMIT RAODEO DM SEMINAR Introduction The incidence of invasive fungal infections in critically ill intensive
More informationMicafungin, a new Echinocandin: Pediatric Development
Micafungin, a new Echinocandin: Pediatric Development Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University
More informationFungi are eukaryotic With rigid cell walls composed largely of chitin rather than peptidoglycan (a characteristic component of most bacterial cell
Antifungal Drugs Fungal infections (Mycoses) Often chronic in nature. Mycotic infections may be superficial and involve only the skin (cutaneous mycoses extending into the epidermis) Others may penetrate
More informationESCMID Online Lecture Library. by author
What is the best antifungal strategy for severe intra-abdominal infections? Philippe Montravers MD, PhD Anaesthesia and Surgical ICU Bichat Claude Bernard Hospital Assistance Publique Hopitaux de Paris
More informationImproving Clinical Outcomes in Fungal Infection Control and Management
Improving Clinical Outcomes in Fungal Infection Control and Management DISCLAIMER The information within this CME/CE activity is for continuing education purposes only, and is not intended to substitute
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More information9/7/2018. Faculty. Overcoming Challenges in the Management of Invasive Fungal Infections. Learning Objectives. Faculty Disclosure
Faculty Overcoming Challenges in the Management of Invasive Fungal James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University Departments of Pharmacy and Infectious
More informationAntifungal Pharmacotherapy
Interpreting Antifungal Susceptibility Testing: Science or Smoke and Mirrors A. W. F O T H E R G I L L, M A, M B A U N I V E R S I T Y O F T E X A S H E A L T H S C I E N C E C E N T E R S A N A N T O
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More information1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans
Jpn. J. Med. Mycol. Vol. 45, 217 221, 2004 ISSN 0916 4804,.,, colonization, pre-emptive therapy. 2, non-albicans Candida., fluconazole.,. Key words: postoperative infection, non-albicans Candida, pre-emptive
More informationSystemic Candidiasis for the clinicians: between guidelines and daily clinical practice
Systemic Candidiasis for the clinicians: between guidelines and daily clinical practice Anastasia Antoniadou Assoc. Professor Internal Medicine and Infectious Diseases National and Kapodistrian University
More informationAntifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences
5th MMTN Conference 5-6 November 2016 Bangkok, Thailand 10:20-10:45, 6 Nov, 2016 Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences Yee-Chun Chen, M.D., PhD. Department of Medicine,
More informationEvidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections. Presenter. Disclosures
Evidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections Presenter James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University
More informationWhat have we learned about systemic antifungals currently available on the market?
2nd ECMM/CEMM Workshop Milano, September 25, 2010 What have we learned about systemic antifungals currently available on the market? Prof. Dr. Georg Maschmeyer Dept. of Hematology, Oncology & Palliative
More informationINFEZIONI FUNGINE E PERCORSI TERAPEUTICI IN ICU. Claudio Viscoli Professor of Infectious Disease University of Genoa
INFEZIONI FUNGINE E PERCORSI TERAPEUTICI IN ICU Claudio Viscoli Professor of Infectious Disease University of Genoa What I would like to discuss with you today When to start an antifungal therapy (before
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationSolid organ transplant patients
M.6 Meet-the-expert sessions Solid organ transplant patients Martin Iversen, Denmark José M. Aguado, Spain Copenhagen, Sunday 13 October 2013 Conflict of interest disclosure In the past 5 years, J.M.A.
More informationNEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003
NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATINS 20th Symposium (spring 2003) Thursday May 22nd 2003 The slides presented at this meeting are available on this site as "Web slide shows" and
More informationCase Studies in Fungal Infections and Antifungal Therapy
Case Studies in Fungal Infections and Antifungal Therapy Wayne L. Gold MD, FRCPC Annual Meeting of the Canadian Society of Internal Medicine November 4, 2017 Disclosures No financial disclosures or industry
More informationWhen is failure failure?
When is failure failure? Bart-Jan Kullberg, M.D. Radboud University Nijmegen The Netherlands The ICU patient with candidemia!! Female, 39 years old!! Multiple abdominal surgeries for Crohn's disease!!
More informationEarly Diagnosis and Therapy for Fungal Infections
Early Diagnosis and Therapy for Fungal Infections Debra Goff PharmD, FCCP Clinical Associate Professor Infectious Disease Specialist The Ohio State University Medical Center Columbus Ohio, USA The Ohio
More informationNew Directions in Invasive Fungal Disease: Therapeutic Considerations
New Directions in Invasive Fungal Disease: Therapeutic Considerations Coleman Rotstein, MD, FRCPC, FACP University of Toronto University Health Network Toronto, Ontario Disclosure Statement for Coleman
More informationUse of Antifungals in the Year 2008
Use of Antifungals in the Year 2008 Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine Diagnosis
More informationCandida auris: an Emerging Hospital Infection
National Center for Emerging and Zoonotic Infectious Diseases Candida auris: an Emerging Hospital Infection Paige Armstrong MD MHS Epidemic Intelligence Service Officer Mycotic Diseases Branch Association
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationAntifungal Stewardship. Önder Ergönül, MD, MPH Koç University, School of Medicine, Istanbul 6 October 2017, ESGAP course, Istanbul
Antifungal Stewardship Önder Ergönül, MD, MPH Koç University, School of Medicine, Istanbul 6 October 2017, ESGAP course, Istanbul 1 2 Objectives What do we know? Invasive Candida and Aspergillosis Impact
More informationWHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU?
WHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU? Empiric antifungal therapy should be considered in critically ill patients with risk factors
More informationAntibiotics 301: Antifungal Agents
Antibiotics 301: Antifungal Agents B. Joseph Guglielmo, Pharm.D. Professor and Dean School of Pharmacy University of California San Francisco Disclosures No potential conflicts of interest. 1 3/3 blood
More informationDr Eggimann collaborated in several industrysponsored. clinical trials since Talk ID: year old BMI 41 Transferred for septic shock
Suggestions to prevent Candida infections Dr Philippe Eggimann, PD&MER Service de Médecine Intensive Adulte www.soins-intensifs.chuv.ch Anything I say can be highly biased Dr Eggimann collaborated in several
More informationAntifungal susceptibility testing: Which method and when?
Antifungal susceptibility testing: Which method and when? Maiken Cavling Arendrup mad@ssi.dk SSI & Juan Luis Rodriguez Tudela jlrtudela@isciii.es ISCIII Agenda Summary of current standards and selected
More informationAntifungal drugs Dr. Raz Muhammed
Antifungal drugs 13. 12. 2018 Dr. Raz Muhammed 2. Flucytosine (5-FC) Is fungistatic Is a synthetic pyrimidine antimetabolite Is often used in combination with amphotericin B in the treatment of systemic
More informationInvasive Fungal Infections in Solid Organ Transplant Recipients
Outlines Epidemiology Candidiasis Aspergillosis Invasive Fungal Infections in Solid Organ Transplant Recipients Hsin-Yun Sun, M.D. Division of Infectious Diseases Department of Internal Medicine National
More informationAntifungal resistance mechanisms in pathogenic fungi
Antifungal resistance mechanisms in pathogenic fungi Shivaprakash M Rudramurthy Additional Professor, Mycology Division Center of Advanced Research in Medical Mycology, National Culture Collection of Pathogenic
More informationReducing the antifungal drugs consumption in the ICU
Reducing the antifungal drugs consumption in the ICU Philippe Montravers Département d Anesthésie et Réanimation Chirurgicale CHU Bichat Claude Bernard Pole TCAUR, HUPNVS Assistance Publique-Hôpitaux de
More informationClinical Considerations in the Management of Systemic Fungal Infections. Conducted during the 41 st ASHP Midyear Clinical Meeting Anaheim, California
Clinical Considerations in the Management of Systemic Fungal Infections Conducted during the 41 st ASHP Midyear Clinical Meeting Anaheim, California CONTINUING EDUCATION ACCREDITATION The American Society
More informationCurrent Options in Antifungal Pharmacotherapy
Current Options in Antifungal Pharmacotherapy John Mohr, Pharm.D., Melissa Johnson, Pharm.D., Travis Cooper, Pharm.D., James S. Lewis, II, Pharm.D., and Luis Ostrosky-Zeichner, M.D. Infections caused by
More informationBSI. Candida auris: A globally emerging multidrug-resistant yeast 5/19/2017. First report of C. auris from Japan in 2009
5/9/7 BSI Candida auris: A globally emerging multidrug-resistant yeast Mycotic Diseases Branch DFWED Friday Seminar August 6, 6 National Center for Emerging and Zoonotic Infectious Diseases Division of
More informationAntifungal Treatment in Neonates
Antifungal Treatment in Neonates Irja Lutsar University of Tartu, Estonia Lisbon, 12. October 2015 Prevalence of invasive fungal infections in NeoINN database 2005-2014 UK; 2012-2014 Estonia & Greece 1
More informationReceived 12 December 2010/Returned for modification 5 January 2011/Accepted 16 March 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1765 1771 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.02517-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multicenter
More informationThe incidence of invasive fungal infections
AN EPIDEMIOLOGIC UPDATE ON INVASIVE FUNGAL INFECTIONS * Michael A. Pfaller, MD ABSTRACT *Based on a presentation given by Dr Pfaller at a symposium held in conjunction with the 43rd Interscience Conference
More informationTOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR
TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS
More informationC. albicans C. tropicalis C. parapsilosis C. kefyr C. glabrata C. krusei C. guillermondii C. lusitaniae THERAPY USING ANTIFUNGALS AND ANTIVIRALS
THERAPY USING ANTIFUNGALS AND ANTIVIRALS Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu CLASSIFICATION OF FUNGI Yeasts Candida Cryptococcus
More informationAmphotericin B Lipid Complex (Abelcet ) 05/06
Amphotericin B Lipid Complex (Abelcet ) Structure and Activity AMB : DMPC : DMPG lipid complex, 10:7:3 mol:mol ribbon-like lipid structures, 1.6-11 µm in diameter binds to ergosterol disturbance of cell
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationVoriconazole. Voriconazole VRCZ ITCZ
7 7 8 7 8 fluconazole itraconazole in vitro in vivo Candida spp. C. glabrata C. krusei Cryptococcus neoformans in vitro Aspergillus spp. in vitro in vivo Aspergillus fumigatus Candida albicans C. krusei
More informationSUSCEPTIBILITY PROFILE OF EMERGING FUNGAL PATHOGENS
SUSCEPTIBILITY PROFILE OF EMERGING FUNGAL PATHOGENS Professor Lia Monica JUNIE, Department of Microbiology, University of Medicine and Pharmacy, Cluj Napoca, Romania The most common fungal pathogens are:
More informationApproach to Fungal Infections
Approach to Fungal Infections Michelle A. Barron, M.D. Professor of Medicine Division of Infectious Diseases University of Colorado Denver Disclosures Research Investigation with Astellas Pharma, US I
More informationUpdates and practical guide on antifungal agents
Updates and practical guide on antifungal agents Dr Atul Patel, MD, FIDSA Chief Consultant and Director Infectious Diseases Clinic Vedanta Institute of Medical Sciences Ahmedabad, India Presented at MMTN
More informationProphylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong
Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic
More informationManagement Strategies For Invasive Mycoses: An MD Anderson Perspective
Management Strategies For Invasive Mycoses: An MD Anderson Perspective Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA Professor of Medicine Director of Mycology Research Program M. D. Anderson Cancer
More informationAbout the Editor Gerri S. Hall, Ph.D.
About the Editor Gerri S. Hall, Ph.D. Dr. Hall s professional career has been focused on clinical microbiology: direct clinical activities of various areas such as bacteriology, mycobacteria, STD testing,
More informationTreatment and Prophylaxis
Treatment and Prophylaxis Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University Children s Hospital
More informationHow Can We Prevent Invasive Fungal Disease?
How Can We Prevent Invasive Fungal Disease? Chris Kibbler Professor of Medical Microbiology University College London And Royal Free Hospital, London, UK Invasive Aspergillosis 2 - Acquisition Preventive
More informationUpdated Guidelines for Management of Candidiasis. Vidya Sankar, DMD, MHS April 6, 2017
Updated Guidelines for Management of Candidiasis Vidya Sankar, DMD, MHS April 6, 2017 Statement of Disclosure I have no actual or potential conflict of interest in relation to this presentation Outline
More information8/24/2015. Objectives (Pharmacists) Azoles: Mechanism of action. Objectives (Technicians)
Objectives (Pharmacists) Invasive fungal infections: What to do if there s a fungus among us Nick O Donnell, PharmD, BCPS Infectious Diseases Pharmacotherapy Fellow List three important interactions and
More informationReceived 18 December 2008/Returned for modification 9 February 2009/Accepted 9 April 2009
JOURNAL OF CLINICAL MICROBIOLOGY, June 2009, p. 1942 1946 Vol. 47, No. 6 0095-1137/09/$08.00 0 doi:10.1128/jcm.02434-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Activity
More informationFungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Fungi Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Cover heading - Topic Outline Topic outline
More informationChallenges and controversies of Invasive fungal Infections
Challenges and controversies of Invasive fungal Infections Mona Al-Dabbagh, MD, MHSc Assistant Professor of Pediatrics, COM-KSAU-HS Consultant Pediatric Infectious Diseases and Transplant Infectious Diseases
More informationAntifungal Therapy in Leukemia Patients
Antifungal Therapy in Leukemia Patients UPDATE ECIL 4, 6 September 2011 Raoul Herbrecht, Ursula Flückiger, Bertrand Gachot, Patricia Ribaud, Anne Thiebaut, Catherine Cordonnier UPDATE ECIL 4, 2011 UPDATE
More informationTherapeutic Options: Where do we stand? Where do we go?
Therapeutic Options: Where do we stand? Where do we go? Oliver A. Cornely MD, FACP, FIDSA, FAAM Chair, Translational Research, CECAD Cluster of Excellence Deputy Head, Division of Infectious Diseases Director,
More informationNational Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing
National Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing Snigdha Vallabhaneni, MD, MPH Medical Epidemiologist Centers for Disease Control and Prevention Invasive Candidiasis
More information9/18/2018. Invasive Candidiasis. AR Lab Network Candida Testing. Most Common Healthcare Associated Bloodstream Infection in the United States?
National Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing Invasive Candidiasis Snigdha Vallabhaneni, MD, MPH Medical Epidemiologist Centers for Disease Control and Prevention
More informationAli J. Olyaei, PharmD, BCPS. Director of Clinical Research Oregon Health & Sciences University
PATH Alliance Registry: Identification of Inappropriate Drug Dosing of Antifungal Agents in Patients with Chronic Kidney Disease Review of 6000 Patients with Fungal Infections Ali J. Olyaei, PharmD, BCPS
More informationSCY-078 ECMM Symposium Cologne, Germany October 2017
A New Path for Antifungal Treatments SCY-078 ECMM Symposium Cologne, Germany October 2017 David Angulo, M.D. Chief Medical Officer SCYNEXIS at a Glance Company created in 2000 Spin-off of Sanofi, initially
More informationNew triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance
For reprint orders, please contact reprints@expert-reviews.com New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance Expert Rev. Anti Infect. Ther. 7(8), 981 998
More informationI am against to TDM in critically ill patient
TDM I am against to TDM in critically ill patient TDM of antifungals: where are we? Dr. Rafael Zaragoza Antifungal therapy in ICU; prophylaxis, pre-emptive and targeted Conflicts of interest: Pfizer Astellas
More informationESCMID Online Lecture Library. by author
How To Best Use Antifungal Agents Cornelia Lass-Flörl Division of Hygiene and Medical Microbiology Innsbruck Medical University ESCMID SUMMER SCHOOL 2012 Epidemiology Diagnosis Roadmap Antifungal drugs
More informationAntifungal Agents. Polyenes Azoles Allyl and Benzyl Amines Other antifungals
OPTO 6434 General Pharmacology Antifungal Agents Dr. Alison McDermott Room 254 HBSB, Phone 713-743 1974 Email amcdermott@optometry.uh.edu Fall 2015 Reading: Chapter 50 Brody s Human Pharmacology by Wecker
More informationCondition First line Alternative Comments Candidemia Nonneutropenic adults
Recommendations for the treatment of candidiasis. Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Condition First line Alternative
More informationNew Options for Prevention & Treatment of Invasive Fungal Infections
New Options for Prevention & Treatment of Invasive Fungal Infections Taylor Sandison, MD, MPH Chief Medical Officer Cidara Therapeutics, Inc. HTIDE 2018, Venice Cidara Pipeline Program Indication Discovery
More informationTrends in Invasive Fungal Infection (IFI) in Haematology-Oncology Patients. Saturday, April 18, 2015 Charlottetown, P.E.I.
Trends in Invasive Fungal Infection (IFI) in Haematology-Oncology Patients Saturday, April 18, 2015 Charlottetown, P.E.I. Moderator & Speaker: Shariq Haider MD, FRCPC, FACP, CCST(UK), DTMH(UK) Professor
More informationAntifungal therapies differences in agents
Antifungal therapies differences in agents The basic Fungi are eukaryotes Eukaryote = an organism whose cells contain complex structures enclosed within membrane. Most Common Fungal Pathogens Dermatophytes
More informationOptimizing antifungal dosing regimens. Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology
ATHENA 2017 International Conference November 28 30, 2017 Optimizing antifungal dosing regimens Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology Clinical Microbiology Laboratory, «Attikon»
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationTerapia empirica e mirata delle infezioni invasive da Candida
Terapia empirica e mirata delle infezioni invasive da Candida Francesco Menichetti, MD Head, Infectious Diseases Unit Ospedale Nuovo Santa Chiara Pisa, Italy Corso Avanzato di Terapia Antibiotica X Edizione
More informationTitle: Author: Speciality / Division: Directorate:
Antifungal guidelines for CANDIDIASIS INFECTIONS (Adults) Proven infection: Targeted antifungal therapy should be prescribed for: o Positive cultures from a sterile site with clinical or radiological abnormality
More informationCommon Fungi. Catherine Diamond MD MPH
Common Fungi Catherine Diamond MD MPH Birth Month and Day & Last Four Digits of Your Cell Phone # BEFORE: http://tinyurl.com/kvfy3ts AFTER: http://tinyurl.com/lc4dzwr Clinically Common Fungi Yeast Mold
More informationResistance epidemiology
ECMM/EFISG symposium: Multidrug resistance in fungi? A formidable foe Resistance epidemiology Ana Alastruey Izquierdo Mycology Reference Lab Spain Instituto de Salud Carlos III Disclousure I have received
More informationLa terapia delle infezioni da Candida. Matteo Bassetti Clinica Malattie infettive A.O.U. San Martino Genova
La terapia delle infezioni da Candida Matteo Bassetti Clinica Malattie infettive A.O.U. San Martino Genova Road map Candidosi invasiva Epidemiologia Distribuzione delle specie Fattori di rischio Timing
More informationAntifungal therapy in children. Adilia Warris MD PhD FRCPCH Clinical Reader Pediatric Infectious Diseases Specialist
Antifungal therapy in children Adilia Warris MD PhD FRCPCH Clinical Reader Pediatric Infectious Diseases Specialist Invasive fungal infections in Pediatrics Children and adolescents are similarly vulnerable
More informationIsolates from a Phase 3 Clinical Trial. of Medicine and College of Public Health, Iowa City, Iowa 52242, Wayne, Pennsylvania ,
JCM Accepts, published online ahead of print on 26 May 2010 J. Clin. Microbiol. doi:10.1128/jcm.00806-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationReceived 4 August 2010/Returned for modification 23 October 2010/Accepted 19 November 2010
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2011, p. 561 566 Vol. 55, No. 2 0066-4804/11/$12.00 doi:10.1128/aac.01079-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Candida
More informationESCMID Online Lecture Library. by author
The antibacterial experience: indications for clinical use of antimicrobial combinations To prevent the emergence of resistant organisms (tuberculosis) To treat polymicrobial infections (abdominal complicated
More informationEMPIRICAL PRESCRIBING GUIDELINES FOR SYSTEMIC FUNGAL INFECTIONS IN ADULTS - HH (1)/CL(G)/651/13
Hampshire Hospitals NHS Foundation Trust Empirical Antifungal Prescribing Guidelines [INSERT UNIQUE POLICY IDENTIFIER] Due for latest review on January 2015. CHECK THE INTRANET FOR LATEST VERSION EMPIRICAL
More informationApplication of PK/PD concepts and the role of TDM in the management of patients with fungal disease. The role of combination therapy as of May 2011
Application of PK/PD concepts and the role of TDM in the management of patients with fungal disease The role of combination therapy as of May 2011 Claudio Viscoli, MD Professor of Infectious Disease Chief,
More informationFungal Infection Pre-Infusion Data
Fungal Infection Pre-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: Event date: / / CIBMTR Form 2046 revision 5 (page 1 of 5). Last Updated May, 2018. Infection Episode
More informationEfficacy of a Novel Echinocandin, CD101, in a Mouse Model of Azole-Resistant Disseminated Candidiasis
Efficacy of a Novel Echinocandin, CD0, in a Mouse Model of Azole-Resistant Disseminated Candidiasis L. Miesel, K-Y Lin, J. C. Chien, M. L. Hsieh, V. Ong, and K. Bartizal Eurofins Panlabs, Taipei, Taiwan
More informationPROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino
PROGRESSI NELLA TERAPIA ANTIFUNGINA A tribute to Piero Martino 1946-2007 ITALIAN ICONS IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI 1961 CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES
More information